CNSystems so further secures its technological advantage to enhance the development of new products for noninvasive, continuous hemodynamic monitoring. The application fields range from prevention over early diagnosis to therapy control and monitoring during life-threatening situations. Especially the noninvasive, continuous measurement of the blood pressure with the CNAP-technology bridges a still open gap in patient monitoring. Up to now there have been two ways to measure blood pressure: either by means of an upper arm cuff, which delivers intermittent results in intervals of a few minutes, or, through an expensive and painful arterial catheter. "We can offer a continuous and noninvasive method being as accurate as the catheter, but as easy to apply as the upper arm measurement", so Dr. Jürgen Fortin, Manager of CNSystems.
The close-meshed patent structure also reflects the company's business strategy: after patenting its basic technology as a first step, CNSystems had methods for monitoring critically ill patients protected. International research teams validated these methods clinically and published their studies in renowned medical journals. Also further parameters such as cardiac output and indicators for fluid responsiveness or the autonomic nervous system, being derived from the well validated blood pressure signal, are covered by patents.
The most recent patent describes a blood pressure sensor which can be produced very cost-effectively which allows for an application as disposable. Especially in the US-health market disposables are favored for hygienic reasons.
"With this innovation we also economically expand our leading position in continuous hemodynamic monitoring. At the same time we save the patent rights within a widespread technological landscape", explains Fortin, who is also co-inventor of all CNSystems patents.
CNSystems will be exhibiting at the International Congress of Intensive Care and Emergency Medicine (ISICEM) in Brussels next week.